Peptide education
Zilucoplan
Zilbrysq · Zilucoplan sodium
Zilucoplan is a prescription peptide that inhibits part of the complement immune system. The U.S. product Zilbrysq treats generalized myasthenia gravis in adults whose blood tests show antibodies against the acetylcholine receptor, called anti-AChR antibodies.
In RAISE, the adjusted mean change on a myasthenia gravis daily-living scale at week 12 was -4.39 points with zilucoplan and -2.30 with placebo. A larger decrease represents greater improvement on that scale.
Overview
Quick answer
The approved indication is specific to generalized disease and anti-AChR-positive adults. Complement inhibition increases the risk of serious meningococcal infection, including in people who have been vaccinated.
What does zilucoplan target?
It binds complement protein C5 and prevents its cleavage, reducing formation of the terminal complement complex. The label says the precise mechanism of benefit in myasthenia gravis is not known.
How is Zilbrysq dosed?
The label specifies one subcutaneous dose each day based on actual body weight: 16.6 mg below 56 kg, 23 mg from 56 kg to under 77 kg, and 32.4 mg at 77 kg or above. Patients may self-inject after training under professional supervision.
What did RAISE measure?
The trial compared change in the MG-ADL score, a measure of symptoms affecting daily activities, over 12 weeks. The average decrease was larger with zilucoplan than placebo.
Does vaccination eliminate infection risk?
No. Serious meningococcal infection can occur despite vaccination. The label calls for recommended vaccination before treatment when possible and urgent evaluation if infection is suspected.
Are there other important precautions?
Pancreatitis and pancreatic cysts have been reported. The label calls for lipase and amylase testing before treatment and discontinuation with appropriate management if pancreatitis is suspected, until it is ruled out or has resolved.
Evidence
Evidence snapshot
The U.S. indication does not cover every form of myasthenia gravis.
At week 12, adjusted mean scores decreased by 4.39 points with zilucoplan and 2.30 with placebo.
A smaller controlled trial evaluated 0.1 and 0.3 mg/kg daily for 12 weeks.
Vaccination lowers risk but does not remove it; Zilbrysq is dispensed through a restricted REMS program.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Zilucoplan improves daily-living symptoms in anti-AChR-positive generalized MG. | In RAISE, 174 adults were randomized to zilucoplan or placebo. The zilucoplan group had a greater mean reduction in MG-ADL score at week 12. | Zilucoplan inhibits C5 cleavage. The label describes the precise connection to clinical benefit in myasthenia gravis as unknown. | Supported for the adult antibody-positive population studied and described in the label. |
| A meningococcal vaccine makes complement inhibition risk-free. | The boxed warning says serious meningococcal infections can occur in vaccinated patients receiving complement inhibitors. | False. Vaccination is part of risk reduction, not a guarantee against infection. | |
| The trial's 0.3 mg/kg is the same format as the labeled dose table. | RAISE used a weight-based 0.3 mg/kg daily study dose. The label instead lists three fixed daily dose strengths assigned by weight band. | Both describe daily subcutaneous treatment, but the dose formats differ. |
Bottom line
Main takeaway
Zilbrysq treats a specific antibody-positive form of generalized myasthenia gravis and requires attention to serious infection symptoms.
The daily dose depends on body weight; vaccination and baseline pancreatic testing are part of the label's safety measures.
RAISE compared change in MG-ADL score at week 12 in anti-AChR-positive adults.
Identity
What it is
Zilucoplan is a 15-amino-acid synthetic macrocyclic peptide. The U.S. label lists single-dose prefilled syringes and autoinjectors in three strengths. UCB described planned later U.S. availability for the autoinjector; its current commercial availability should be confirmed.
Complement is part of immune defense. Inhibiting C5 also increases susceptibility to serious meningococcal infection, which is why the product has a boxed warning and a restricted distribution program.
Use context
Routes, doses, and cycle patterns
Zilbrysq is given once daily under healthcare-professional supervision, with the dose determined by weight.
Human studies and product labels
Zilbrysq U.S. label
- Purpose
- Anti-AChR-positive generalized myasthenia gravis in adults
- Context
- Label-reported prescription use
- Route
- Subcutaneous injection
- Amount
- Under 56 kg, 16.6 mg; 56 kg to under 77 kg, 23 mg; 77 kg or above, 32.4 mg.
- Frequency
- Once daily
Patients may self-inject after training; meningococcal precautions and baseline lipase and amylase testing apply.
RAISE phase 3 trial
- Purpose
- Change in the MG-ADL score
- Context
- Randomized placebo-controlled study
- Route
- Subcutaneous injection
- Amount
- 0.3 mg/kg versus placebo
- Frequency
- Once daily
- Duration
- 12 weeks
The adjusted mean week-12 score decrease was 4.39 points versus 2.30 with placebo.
Phase 2 dose-ranging trial
- Purpose
- Myasthenia gravis symptom and function scores
- Context
- Randomized placebo-controlled study
- Route
- Subcutaneous injection
- Amount
- 0.1 or 0.3 mg/kg versus placebo
- Frequency
- Once daily
- Duration
- 12 weeks
These weight-based research arms were studied before the labeled fixed-dose weight bands.
Research
Research evidence
The phase 3 RAISE trial found a greater average improvement in MG-ADL scores than placebo over 12 weeks. A smaller phase 2 trial provides additional dose-ranging evidence in anti-AChR-positive generalized disease.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| RAISE | 174 randomized adults with anti-AChR-positive generalized MG | Double-blind, placebo-controlled phase 3 trial | Zilucoplan 0.3 mg/kg subcutaneously each day versus placebo | Adjusted mean MG-ADL change at week 12 was -4.39 versus -2.30 points. | The 12-week comparison involved a selected antibody-positive population. | Strong |
| Phase 2 dose-ranging study | 44 people with moderate-to-severe anti-AChR-positive generalized MG | Double-blind, placebo-controlled randomized trial | Two daily weight-based subcutaneous doses versus placebo | The 0.3 mg/kg group improved on myasthenia gravis clinical scales compared with placebo. | The small trial cannot establish the frequency of uncommon adverse effects. | Moderate |
Cautions
Safety and unknowns
- Serious meningococcal infection can progress rapidly and has occurred with complement inhibitors even after vaccination. Symptoms of a serious infection require immediate medical evaluation.
- The label calls for meningococcal vaccination at least 2 weeks before treatment when possible. If treatment is urgent and vaccination is not up to date, it describes antibacterial prophylaxis and vaccination as soon as possible.
- Zilbrysq must not be started during an unresolved serious meningococcal infection. Prescribers and pharmacies participate in the product's REMS program.
- Serious infections from other Neisseria species, including disseminated gonorrhea, have been reported with complement inhibitors. The label also warns of increased susceptibility to pneumococcal and Haemophilus influenzae infections. It calls for pneumococcal vaccination according to current recommendations and gonorrhea prevention counseling and testing for people at risk.
- Pancreatitis and pancreatic cysts have been reported. The label calls for baseline lipase and amylase testing and discontinuation with appropriate management if pancreatitis is suspected, until it is ruled out or has resolved.
- The label says Zilbrysq may cause fetal harm based on animal data. There are no available human pregnancy data sufficient to assess drug-associated risk; increased embryofetal deaths occurred in pregnant monkeys at exposures similar to those in humans receiving therapeutic doses.
- Injection-site reactions, upper respiratory infections, and diarrhea were among the most common adverse reactions. Pediatric safety and effectiveness have not been established.
Product quality
Product identity and quality
The U.S. label lists single-dose prefilled syringes and autoinjectors in three strengths. UCB described planned later availability for the autoinjector; approval alone does not establish current commercial availability.
Weight and dose strength
The labeled daily amount depends on actual body weight.
Infection safeguards
Vaccination, REMS participation, and monitoring address a serious risk that persists during treatment.
Mechanism
How it is proposed to work
Zilucoplan blocks activation of C5, reducing formation of a complement complex that can damage cell membranes. The label says its precise therapeutic mechanism in generalized myasthenia gravis is not known.
The label proposes reduced terminal complement deposition at the neuromuscular junction as a possible explanation for benefit.
Details
Technical details
Sources
References
- 1.
DailyMed. Zilbrysq prescribing information
- 2.
- 3.
- 4.
- 5.
PubMed. RAISE randomized trial in generalized myasthenia gravis
doi:10.1016/S1474-4422(23)00080-7 PMID:37059508 NCT04115293
- 6.
PubMed. Phase 2 randomized trial in generalized myasthenia gravis
PMID:32065623